AGÕæÈ˹ٷ½

STOCK TITAN

Performant Healthcare, Inc. Announces Financial Results for First Quarter 2025

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Negative)
Tags

PLANTATION, Fla.--(BUSINESS WIRE)-- Performant Healthcare, Inc. (Nasdaq: PHLT), a leading provider of healthcare payment integrity services, today reported the following financial results for its first quarter ended March 31, 2025:

First Quarter 2025 Financial Highlights

  • Total revenue of $33.3 million, compared to total revenue of $27.3 million in the prior year period.
  • Healthcare revenue of $33.2 million, compared to $25.8 million in the prior year period, an increase of approximately 29%.
  • Net loss of $0.1 million, or $0.00 per diluted share, compared to net loss of $4.0 million, or $(0.05) per diluted share, in the prior year period.
  • Adjusted EBITDA of $3.3 million, compared to $(1.2) million in the prior year period.
  • Adjusted net income was $1.2 million, or $0.02 per diluted share, compared to adjusted net loss of $3.0 million, or $(0.04) per diluted share, in the prior year period.

First Quarter 2025 Results

Total revenue in the first quarter of 2025 was $33.3 million, an increase of 22% from total revenue of $27.3 million in the prior year period. Healthcare revenue was $33.2 million in the first quarter of 2025, representing an increase of approximately 29% from $25.8 million in the prior year period. Claims-based services revenue in the first quarter of 2025 was $17.1 million, while revenue from eligibility-based services in the first quarter was $16.1 million, an increase of 38% and 20%, respectively, over the same prior year period.

“Our first quarter revenue and profitability exceeded expectations, underscoring our commitment to a results-driven healthcare strategy,� stated Simeon Kohl, CEO of Performant. "Our quarterly results highlight the demand for Performant’s services and the robustness of our business model. We saw solid growth across both government and commercial clients in the quarter with the majority of growth continuing to come from commercial clients. In the first quarter, we implemented 13 commercial programs, estimated to contribute between $4.5 million and $5.0 million in annualized revenue at steady state. Amid an uncertain political and healthcare environment, Performant is well-positioned to provide clients with certainty and savings. Our mission is unchanged, we are committed to reducing wasteful spend in the healthcare system and we are dedicated to delivering sustainable growth and profitable expansion for our shareholders."

Net loss for the first quarter was $0.1 million, or $0.00 per diluted share, compared to a net loss of $4.0 million, or $(0.05) per diluted share, in the prior year period. Adjusted EBITDA for the first quarter was $3.3 million as compared to $(1.2) million in the prior year period. Adjusted net income for the first quarter was $1.2 million, or $0.02 per share on a diluted basis, compared to adjusted net loss of $3.0 million, or $(0.04) per diluted share, in the prior year period.

"The strong start to the year gives us confidence to increase full-year adjusted EBITDA and revenue guidance," said Rohit Ramchandani, Chief Financial Officer. "These solid first-quarter results are a testament to our commitment and execution of the strategy set forth in 2021 when we transitioned to a pure-play healthcare company. With commercial clients, our largest growth area, we continue to see strong momentum driven by solid performance, a healthy pipeline, successful implementations, and a growing backlog of new contract awards that have yet to fully scale. We expect to deliver 2025 healthcare revenues in the range of $133 million to $135 million and adjusted EBITDA in the range of $9 million to $10 million. This increase in guidance reflects our solid first-quarter results and our optimistic outlook for the remainder of the year," Ramchandani further commented.

Note Regarding Use of Non-GAAP Financial Measures

In this press release, to supplement our consolidated financial statements, the Company presents adjusted EBITDA, adjusted net income (loss), and adjusted net income (loss) per diluted share. These measures are not in accordance with accounting principles generally accepted in the United States of America (US GAAP) and accordingly reconciliations of adjusted EBITDA and adjusted net income (loss) to net income (loss) determined in accordance with US GAAP are included in the “Reconciliation of Non-GAAP Results� table at the end of this press release. We have included adjusted EBITDA and adjusted net income (loss) in this press release because they are key measures used by our management and board of directors to understand and evaluate our core operating performance and trends and to prepare and approve our annual budget. Accordingly, we believe that adjusted EBITDA and adjusted net income (loss) provide useful information to investors and analysts in understanding and evaluating our operating results in the same manner as our management and board of directors. Our use of adjusted EBITDA and adjusted net income (loss) has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our results as reported under US GAAP. In particular, many of the adjustments to our US GAAP financial measures reflect the exclusion of items, specifically interest, tax, and depreciation and amortization expenses, equity-based compensation expense and certain other non-operating expenses, that are recurring and will be reflected in our financial results for the foreseeable future. In addition, these measures may be calculated differently from similarly titled non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes. In regard to forward looking non-GAAP guidance, we are not able to reconcile the forward-looking non-GAAP adjusted EBITDA measure to the closest corresponding GAAP measure without unreasonable efforts because we are unable to predict the ultimate outcome of certain significant items. These items include, but are not limited to, impacts associated with interest expense, and depreciation and amortization expenses.

Earnings Conference Call

The Company will hold a conference call to discuss its first quarter 2025 results today at 5:00 p.m. Eastern. A live webcast of the call may be accessed on the Investor Relations section of the Company’s website at investors.performantcorp.com. To dial into the call you can dial 800-717-1738 or 646-307-1865.

A replay of the call will be available on the Company's website or by dialing 844-512-2921 (domestic) or 412-317-6671 (international) and entering the passcode 1176510. The telephonic replay will be available approximately three hours after the call, through May 15, 2025.

About Performant Healthcare, Inc.

Performant supports healthcare payers in identifying, preventing, and recovering waste and improper payments by leveraging advanced technology, analytics and proprietary data assets. Performant works with leading national and regional healthcare payers to provide eligibility-based, also known as coordination-of-benefits (COB) services, as well as claims-based services, which includes the audit and identification of improperly paid claims. Performant is a leading provider of these services in both government and commercial healthcare markets. Performant also provides advanced reporting capabilities, support services, customer care, and stakeholder training programs designed to mitigate future instances of improper payments.

To learn more, please visit

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's outlook for revenues, net income (loss), adjusted EBITDA in 2025 and beyond, our commercial client growth strategy, and our estimated revenue from commercial programs implemented in the first quarter of 2025. These forward-looking statements are based on current expectations, estimates, assumptions, and projections that are subject to change and actual results may differ materially from the forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company’s ability to generate revenue following long implementation periods associated with new customer contracts; the high level of revenue concentration among our largest customers; client relationships and the Company’s ability to maintain such client relationships; many of the Company’s customer contracts are subject to periodic renewal, are not exclusive, do not provide for committed business volumes; anticipated trends and challenges in the Company’s business and competition in the markets in which it operates; the Company’s indebtedness and compliance, or failure to comply, with restrictive covenants in the Company’s credit agreement; opportunities and expectations for growth in the various markets in which the Company operates; the Company’s ability to hire and retain employees with specialized skills that are required for its healthcare business; downturns in domestic or global economic conditions and other macroeconomic factors; the Company’s ability to generate sufficient cash flows to fund our ongoing operations and other liquidity needs; the impact of public health pandemics such as COVID-19 on the Company’s business and operations, opportunities and expectations for the markets in which the Company operates; the impacts of a failure of the Company’s operating systems or technology infrastructure or those of third-party vendors and subcontractors; the impacts of a cybersecurity breach or related incident to the Company or any of the Company’s third-party vendors and subcontractors; the adaptability of the Company’s technology platform to new markets and processes; the Company’s ability to invest in and utilize our data and analytics capabilities to expand its capabilities; the Company’s growth strategy of expanding in existing markets and considering strategic alliances or acquisitions; the Company’s ability to maintain, protect and enhance its intellectual property; expectations regarding future expenses; expected future financial performance; and the Company’s ability to comply with and adapt to industry regulations and compliance demands.

More information on potential factors that could affect the Company's financial condition and operating results is included from time to time in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's annual report on Form 10-K for the year ended December 31, 2024 and subsequently filed reports on Forms 10-Q and 8-K. The forward-looking statements are made as of the date of this press release and the Company does not undertake to update any forward-looking statements to conform these statements to actual results or revised expectations.

PERFORMANT HEALTHCARE, INC. AND SUBSIDIARIES

Consolidated Balance Sheets

(In thousands, except par value amounts)

Ìý

Ìý

March 31,
2025

December 31,
2024

Ìý

(Unaudited)

Ìý

Assets

Ìý

Ìý

Current assets:

Ìý

Ìý

Cash and cash equivalents

$

9,981

Ìý

$

9,292

Ìý

Trade accounts receivable, net of allowance for credit losses

Ìý

14,713

Ìý

Ìý

14,165

Ìý

Contract assets

Ìý

13,059

Ìý

Ìý

10,876

Ìý

Prepaid expenses and other current assets

Ìý

4,217

Ìý

Ìý

3,991

Ìý

Income tax receivable

Ìý

�

Ìý

Ìý

34

Ìý

Total current assets

Ìý

41,970

Ìý

Ìý

38,358

Ìý

Property, equipment, and software, net

Ìý

14,025

Ìý

Ìý

14,021

Ìý

Goodwill

Ìý

47,372

Ìý

Ìý

47,372

Ìý

Debt issuance costs

Ìý

359

Ìý

Ìý

416

Ìý

Right-of-use assets

Ìý

867

Ìý

Ìý

826

Ìý

Other assets

Ìý

772

Ìý

Ìý

781

Ìý

Total assets

$

105,365

Ìý

$

101,774

Ìý

Liabilities and Stockholders� Equity

Ìý

Ìý

Current liabilities:

Ìý

Ìý

Accrued salaries and benefits

Ìý

10,699

Ìý

Ìý

8,502

Ìý

Accounts payable

Ìý

1,347

Ìý

Ìý

482

Ìý

Other current liabilities

Ìý

1,807

Ìý

Ìý

2,091

Ìý

Income taxes payable

Ìý

35

Ìý

Ìý

�

Ìý

Contract liabilities

Ìý

591

Ìý

Ìý

753

Ìý

Estimated liability for appeals and disputes

Ìý

543

Ìý

Ìý

517

Ìý

Deferred asset acquisition payments

Ìý

1,216

Ìý

Ìý

1,243

Ìý

Lease liabilities

Ìý

163

Ìý

Ìý

383

Ìý

Total current liabilities

Ìý

16,401

Ìý

Ìý

13,971

Ìý

Long-term loan payable

Ìý

8,000

Ìý

Ìý

8,000

Ìý

Deferred asset acquisition payments

Ìý

2,015

Ìý

Ìý

2,686

Ìý

Lease liabilities

Ìý

723

Ìý

Ìý

462

Ìý

Other liabilities

Ìý

94

Ìý

Ìý

156

Ìý

Total liabilities

Ìý

27,233

Ìý

Ìý

25,275

Ìý

Commitments and contingencies

Ìý

Ìý

Stockholders� equity:

Ìý

Ìý

Common stock, $0.0001 par value. Authorized, 500,000 shares at March 31, 2025 and December 31, 2024 respectively; issued and outstanding 78,309 and 78,309 shares at March 31, 2025 and December 31, 2024, respectively

Ìý

8

Ìý

Ìý

8

Ìý

Additional paid-in capital

Ìý

153,402

Ìý

Ìý

151,688

Ìý

Accumulated deficit

Ìý

(75,278

)

Ìý

(75,197

)

Total stockholders� equity

Ìý

78,132

Ìý

Ìý

76,499

Ìý

Total liabilities and stockholders� equity

$

105,365

Ìý

$

101,774

Ìý

PERFORMANT HEALTHCARE, INC. AND SUBSIDIARIES

Consolidated Statements of Operations

(In thousands, except per share amounts)

(Unaudited)

Ìý

Ìý

Three Months Ended

March 31,

Ìý

2025

2024

Revenues

$

33,269

Ìý

$

27,334

Ìý

Operating expenses:

Ìý

Ìý

Salaries and benefits

Ìý

25,358

Ìý

Ìý

23,221

Ìý

Other operating expenses

Ìý

7,761

Ìý

Ìý

8,034

Ìý

Total operating expenses

Ìý

33,119

Ìý

Ìý

31,255

Ìý

Income (loss) from operations

Ìý

150

Ìý

Ìý

(3,921

)

Interest expense

Ìý

(289

)

Ìý

(186

)

Interest income

Ìý

98

Ìý

Ìý

106

Ìý

Loss before provision for income taxes

Ìý

(41

)

Ìý

(4,001

)

Provision for income taxes

Ìý

40

Ìý

Ìý

16

Ìý

Net loss

$

(81

)

$

(4,017

)

Net loss per share

Ìý

Ìý

Basic

$

�

Ìý

$

(0.05

)

Diluted

$

�

Ìý

$

(0.05

)

Weighted average shares

Ìý

Ìý

Basic

Ìý

78,309

Ìý

Ìý

76,920

Ìý

Diluted

Ìý

78,309

Ìý

Ìý

76,920

Ìý

Ìý

PERFORMANT HEALTHCARE, INC. AND SUBSIDIARIES

Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

Ìý

Ìý

Three Months Ended

March 31,

Ìý

2025

2024

Cash flows from operating activities:

Ìý

Ìý

Net loss

$

(81

)

$

(4,017

)

Adjustments to reconcile net loss to net cash provided by operating activities:

Ìý

Ìý

Loss on disposal of assets

Ìý

�

Ìý

Ìý

29

Ìý

Depreciation and amortization

Ìý

1,452

Ìý

Ìý

1,398

Ìý

Right-of-use assets amortization

Ìý

146

Ìý

Ìý

108

Ìý

Stock-based compensation

Ìý

1,714

Ìý

Ìý

957

Ìý

Interest expense from debt issuance costs

Ìý

56

Ìý

Ìý

58

Ìý

Interest accretion on deferred asset acquisition

Ìý

67

Ìý

Ìý

�

Ìý

Changes in operating assets and liabilities:

Ìý

Ìý

Trade accounts receivable

Ìý

(548

)

Ìý

3,301

Ìý

Contract assets

Ìý

(2,183

)

Ìý

(1,000

)

Prepaid expenses and other current assets

Ìý

(226

)

Ìý

(480

)

Income tax receivable

Ìý

34

Ìý

Ìý

335

Ìý

Other assets

Ìý

3

Ìý

Ìý

325

Ìý

Accrued salaries and benefits

Ìý

2,197

Ìý

Ìý

(1,850

)

Accounts payable

Ìý

865

Ìý

Ìý

1,424

Ìý

Contract liabilities and other current liabilities

Ìý

(446

)

Ìý

(365

)

Income taxes payable

Ìý

35

Ìý

Ìý

7

Ìý

Estimated liability for appeals and disputes

Ìý

26

Ìý

Ìý

(10

)

Lease liabilities

Ìý

(146

)

Ìý

(106

)

Other liabilities

Ìý

(61

)

Ìý

7

Ìý

Net cash provided by operating activities

Ìý

2,904

Ìý

Ìý

121

Ìý

Cash flows from investing activities:

Ìý

Ìý

Purchase of property, equipment, and software

Ìý

(1,450

)

Ìý

(3,652

)

Net cash used in investing activities

Ìý

(1,450

)

Ìý

(3,652

)

Cash flows from financing activities:

Ìý

Ìý

Debt issuance costs paid

Ìý

�

Ìý

Ìý

(14

)

Deferred asset acquisition payments made

Ìý

(765

)

Ìý

�

Ìý

Net cash used in financing activities

Ìý

(765

)

Ìý

(14

)

Net increase (decrease) in cash and cash equivalents

Ìý

689

Ìý

Ìý

(3,545

)

Cash and cash equivalents at beginning of period

Ìý

9,292

Ìý

Ìý

7,333

Ìý

Cash and cash equivalents at end of period

$

9,981

Ìý

$

3,788

Ìý

Non-cash investing activities:

Ìý

Ìý

Deferred asset acquisition payments

$

�

Ìý

$

3,718

Ìý

Supplemental disclosures of cash flow information:

Ìý

Ìý

Cash paid (received) for income taxes

$

4

Ìý

$

(304

)

Cash paid for interest

$

227

Ìý

$

127

Ìý

PERFORMANT HEALTHCARE, INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Results

(In thousands, except per share amount)

(Unaudited)

Ìý

Ìý

Three Months Ended

March 31,

Ìý

2025

2024

Ìý

(in thousands)

Adjusted EBITDA:

Ìý

Ìý

Net income (loss)

$

(81

)

$

(4,017

)

Provision for income taxes

Ìý

40

Ìý

Ìý

16

Ìý

Interest expense (1)

Ìý

289

Ìý

Ìý

186

Ìý

Interest income

Ìý

(98

)

Ìý

(106

)

Stock-based compensation

Ìý

1,714

Ìý

Ìý

957

Ìý

Depreciation and amortization

Ìý

1,452

Ìý

Ìý

1,398

Ìý

Severance expenses (3)

Ìý

�

Ìý

Ìý

336

Ìý

Other

Ìý

6

Ìý

Ìý

�

Ìý

Adjusted EBITDA

$

3,322

Ìý

$

(1,230

)

Ìý

Three Months Ended

March 31,

Ìý

2025

2024

Ìý

(in thousands)

Adjusted Net Income (Loss):

Ìý

Ìý

Net income (loss)

$

(81

)

$

(4,017

)

Stock-based compensation

Ìý

1,714

Ìý

Ìý

957

Ìý

Amortization of debt issuance costs (2)

Ìý

63

Ìý

Ìý

58

Ìý

Severance expenses (3)

Ìý

�

Ìý

Ìý

336

Ìý

Other

Ìý

6

Ìý

Ìý

�

Ìý

Tax adjustments (4)

Ìý

(490

)

Ìý

(372

)

Adjusted net income (loss)

$

1,212

Ìý

$

(3,038

)

Ìý

Three Months Ended

March 31,

Ìý

2025

2024

Ìý

(in thousands)

Adjusted Net Income (Loss) Per Diluted Share:

Ìý

Ìý

Net income (loss)

$

(81

)

$

(4,017

)

Plus: Adjustment items per reconciliation of adjusted net income (loss)

Ìý

1,293

Ìý

Ìý

979

Ìý

Adjusted net income (loss)

$

1,212

Ìý

$

(3,038

)

Adjusted net income (loss) per diluted share

$

0.02

Ìý

$

(0.04

)

Diluted average shares outstanding (5)

Ìý

79,407

Ìý

Ìý

76,920

Ìý

(1)

Primarily represents interest expense and amortization of debt issuance costs related to our Credit Agreement.

(2)

Represents amortization of debt issuance costs related to our Credit Agreement.

(3)

Represents severance expenses incurred in connection with a reduction in force for our non-healthcare recovery services.

(4)

Represents tax adjustments assuming a marginal tax rate of 27.5% at full profitability.

(5)

While net loss for the three months ended March 31, 2025 is ($81), the computation of adjusted net income (loss) results in adjusted net income of $1,212. Therefore, the calculation of the adjusted net income (loss) per diluted share for the three months ended March 31, 2025 includes dilutive common share equivalents of 1,098 added to the basic weighted average shares of 78,309.

We are providing the following historical breakdown of the quarterly and annual revenue contributions under the contribution breakdowns of our healthcare revenue results for the three months ended March 31, 2025, and for the years ended December 31, 2024, 2023 and 2022:

PERFORMANT HEALTHCARE, INC. AND SUBSIDIARIES

Quarterly and Annual Revenues

(In thousands)

(Unaudited)

Ìý

Ìý

Three Months Ended

Ìý

March 31, 2025

Ìý

Ìý

Eligibility-based

$

16,082

Claims-based

Ìý

17,104

Healthcare Total

Ìý

33,186

Customer Care / Outsourced Services

Ìý

83

Total

$

33,269

Ìý

Ìý

Ìý

Three Months Ended

Ìý

Year Ended

Ìý

March 31, 2024

June 30, 2024

September 30, 2024

December 31, 2024

December 31, 2024

Ìý

(in thousands)

Eligibility-based

$

13,388

$

14,264

$

16,070

$

18,138

$

61,860

Claims-based

Ìý

12,412

Ìý

13,661

Ìý

14,217

Ìý

16,141

Ìý

56,431

Healthcare Total

Ìý

25,800

Ìý

27,925

Ìý

30,287

Ìý

34,279

Ìý

118,291

Customer Care / Outsourced Services

Ìý

1,534

Ìý

1,437

Ìý

1,232

Ìý

487

Ìý

4,690

Total

$

27,334

$

29,362

$

31,519

$

34,766

$

122,981

Ìý

Three Months Ended

Year Ended

Ìý

March 31, 2023

June 30, 2023

September 30, 2023

December 31, 2023

December 31, 2023

Ìý

(in thousands)

Eligibility-based

$

12,480

$

14,131

$

18,165

$

16,403

$

61,179

Claims-based

Ìý

10,412

Ìý

9,798

Ìý

10,325

Ìý

14,730

Ìý

45,265

Healthcare Total

Ìý

22,892

Ìý

23,929

Ìý

28,490

Ìý

31,133

Ìý

106,444

Recovery

Ìý

19

Ìý

14

Ìý

�

Ìý

�

Ìý

33

Customer Care / Outsourced Services

Ìý

2,818

Ìý

1,542

Ìý

1,472

Ìý

1,434

Ìý

7,266

Total

$

25,729

$

25,485

$

29,962

$

32,567

$

113,743

Ìý

Three Months Ended

Year Ended

Ìý

March 31, 2022

June 30, 2022

September 30, 2022

December 31, 2022

December 31, 2022

Ìý

(in thousands)

Eligibility-based

$

14,214

$

12,417

$

13,142

$

13,511

$

53,284

Claims-based

Ìý

9,150

Ìý

9,339

Ìý

10,377

Ìý

12,516

Ìý

41,382

Healthcare Total

Ìý

23,364

Ìý

21,756

Ìý

23,519

Ìý

26,027

Ìý

94,666

Recovery

Ìý

118

Ìý

7

Ìý

41

Ìý

75

Ìý

241

Customer Care / Outsourced Services

Ìý

3,601

Ìý

3,918

Ìý

3,618

Ìý

3,140

Ìý

14,277

Total

$

27,083

$

25,681

$

27,178

$

29,242

$

109,184

Ìý

Jon Bozzuto

Investor Relations

925-960-4988

[email protected]

Source: Performant Healthcare, Inc.

Performant Finl Corp

NASDAQ:PHLT

PHLT Rankings

PHLT Latest News

PHLT Latest SEC Filings

PHLT Stock Data

270.16M
69.31M
8.1%
85.05%
1.28%
Health Information Services
Services-miscellaneous Business Services
United States
PLANTATION